Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
CMV Infection, EBV or Adenovirus
and you are
between 1 and 70
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

To assess the safety and biological efficacy of therapeutically administered most closely HLA-matched third party donor-derived specific cytotoxic T lymphocytes (CTLs) targeting cytomegalovirus (CMV) or Adenovirus (Adv) or Epstein Barr virus (EBV) or fungi including Aspergillus and Candida species for the treatment of viral infection following allogeneic blood or marrow stem cell or solid organ transplantation.

Provided treatments

  • Biological: Virus specific CTLs
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02779439. The sponsor of the trial is University of Sydney and it is looking for 25 volunteers for the current phase.
Official trial title:
Therapeutic Infusion of Partially HLA-matched Third Party Donor-derived Virus- and Fungus Specific T-lymphocytes in Patients With Active Viral or Fungal Infection Post-allogeneic Stem Cell or Solid Organ Transplantation